A Clinical Research of Echocardiography and MRI new technology in Prediction of Cardiotoxicity in Ovarian Cancer Patients Recerving Chemotherapy

The utilities of Echocardiography and MRI new technology in early monitoring and predition of Cardiotoxicity in Ovarian Cancer Patients Recerving Chemotherapy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-DDD-17013450

Enrollment

Unknown

Registered

2017-11-20

Start date

2018-07-01

Completion date

Unknown

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chemotherapy-induced cardiotoxicity

Interventions

Gold Standard:cTn, BNP, ECG

Index test:echocardiography&#32

and&#32

MRI

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients of at least 18 years of age newly diagnosed with ovarian cancer and scheduled to receive chemotherapy including anthracycline or taxol.

Exclusion criteria

Exclusion criteria: (1) Patients who have a baseline LVEF<50%; (2) presence of other systemic diseases associated with cardiovascular damage; (3) contraindication for MRI due to the presence of cardiac pacemaker or defibrillators and other unsafe ferromagnetic objects; (4) claustrophobia; (5) severe arrhythmia.

Design outcomes

Primary

Measure	Time frame
Strain measured by 2D and 3D speckle tracking echocardiography;T2 imaging features;T1 imaging features, including native T1 and ECV;SPE, SEN, ROC;	—

Countries

China

Contacts

Public ContactYingkun Guo

West China Second University Hospital, Sichuan University

gykpanda@163.com+86 18980006572

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026